证券代码：000623 证券简称：吉林敖东 公告编号:2025-063 吉林敖东药业集团股份有限公司 关于公开发行可转换公司债券部分募集资金专户销户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准吉林敖东药业集团股份有限公司公开 发行可转换公司债券的批复》（证监许可[2018]184 号）核准，吉林敖东药业集 团股份有限公司（以下简称"公司"）于 2018 年 3 月 13 日公开发行了面值总额 241,300 万元的可转换公司债券，扣除发行费用 2,446.13 万元后，募集资金净 额为 238,853.87 万元。截至 2018 年 3 月 19 日，上述募集资金已经到位。中准 会计师事务所（特殊普通合伙）已对上述募集资金到位情况出具了验资报告。 二、募集资金存放和管理情况 （一）募集资金管理情况 为了规范募集资金的管理和使用，保护投资者权益，本公司修订了《募集资 金管理办法》。该管理办法经公司第九届董事会第二次会议、第九届监事会第二 次会议、2017 年第二次临时股东大会决议通过；经公司第十 ...

Core Viewpoint - The Chinese traditional medicine sector, particularly the Chinese Medicine ETF (560080), is experiencing increased investor interest due to favorable market conditions and relatively low valuations, with a notable inflow of funds and positive performance in recent trading sessions [1][3][10]. Group 1: Market Performance - On November 10, the Shanghai Composite Index rose by 0.53%, with the consumer sector leading gains, particularly the Chinese medicine segment, which saw the Chinese Medicine ETF (560080) increase by 1.55% and a trading volume exceeding 160 million yuan [1]. - The Chinese Medicine ETF (560080) has seen a cumulative net inflow of over 260 million yuan in the past 20 days, bringing its total fund size to over 2.8 billion yuan, leading its peers significantly [1][3]. Group 2: Valuation Insights - As of November 7, the TTM price-to-earnings (PE) ratio of the Chinese Medicine ETF (560080) was 25.31, placing it at the 24.5% percentile over the past decade, indicating that the index is cheaper than 75% of the time historically [3]. - The TTM PE ratio is just 0.57 away from the calculated opportunity value, suggesting a higher cost-performance ratio for potential investors [3]. Group 3: Stock Performance - Most constituent stocks of the Chinese Medicine ETF (560080) showed positive performance, with notable gains from Yunnan Baiyao, Pianzaihuang, and Yiling Pharmaceutical, all rising over 2%, while others like Tongrentang and Dong'e Ejiao also saw increases [5][6]. Group 4: Industry Trends - The Chinese medicine index has shown negative returns year-to-date, with a decline of 0.24% this year and an 8.13% drop in 2024, indicating a challenging market environment [7]. - Despite recent struggles, analysts suggest that the sector may be approaching a turning point, with potential improvements in performance expected due to rising flu incidence and better management of inventory levels among leading OTC Chinese medicine companies [10][11]. Group 5: Institutional Insights - Analysts from Zheshang Securities highlight that the Chinese medicine industry has characteristics similar to the banking sector, with strong cash flow and stable profit growth, suggesting resilience against external shocks [11]. - The industry is expected to see improved revenue growth in the second half of 2025, driven by declining raw material prices and cost-cutting measures by companies [11].

Core Viewpoint - Jilin Aodong's stock price has shown a significant increase this year, with a notable rise in net profit despite a decrease in revenue, indicating potential resilience in its business model and market positioning [1][2]. Financial Performance - As of September 30, 2025, Jilin Aodong reported a revenue of 1.64 billion yuan, a year-on-year decrease of 14.10%, while the net profit attributable to shareholders was 2.26 billion yuan, reflecting a year-on-year increase of 81.70% [2]. - The company's stock price increased by 28.67% year-to-date, with a 0.84% rise over the last five trading days, 6.18% over the last 20 days, and 13.91% over the last 60 days [1]. Shareholder Information - The number of shareholders decreased by 7.18% to 61,200, while the average circulating shares per person increased by 7.73% to 19,456 shares [2]. - The company has distributed a total of 4.664 billion yuan in dividends since its A-share listing, with 1.881 billion yuan distributed in the last three years [3]. Ownership Structure - As of September 30, 2025, the top ten circulating shareholders included Southern CSI 500 ETF, holding 13.93 million shares (a decrease of 317,900 shares), and Hong Kong Central Clearing Limited, holding 11.82 million shares (a decrease of 319,620 shares) [3].

Core Insights - The Chinese medicine market is experiencing rapid growth, driven by favorable policies and increasing market demand, as highlighted by the recent 12th World Traditional Chinese Medicine Conference held in Sydney, Australia [1][2]. Group 1: Market Performance - As of November 10, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 1.11%, with notable increases in stocks such as Zhongsheng Pharmaceutical (002317) up 3.69% and Kangyuan Pharmaceutical (600557) up 3.22% [1]. - The Traditional Chinese Medicine ETF (159647) increased by 0.88%, with the latest price reported at 1.03 yuan [1]. Group 2: Industry Growth Drivers - The conference attracted over 800 representatives from 24 countries, emphasizing the global interest in the dissemination and technological innovation of traditional Chinese medicine [1]. - Pacific Securities notes that the industry is supported by comprehensive measures across supply, payment, and demand sides, including registration, review, quality control, and cultural promotion [1]. Group 3: Key Constituents - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.92% of the index, including major players like Yunnan Baiyao (000538) and Tongrentang (600085) [2].

Group 1 - The company held its 20th meeting of the 11th Board of Directors on November 6, 2025, with all 9 directors present, including independent directors attending via remote voting [1][3][4] - The meeting approved the proposal regarding the resignation and re-election of an independent director, with a unanimous vote of 9 in favor [3][5] - The company plans to hold its second extraordinary general meeting of shareholders on November 24, 2025, at 14:00 [4][5] Group 2 - The independent director Liang Biming submitted his resignation on November 5, 2025, due to personal reasons, and will continue to fulfill his duties until a new independent director is elected [77][78] - Zhang Chunying has been nominated as the candidate for the independent director position, recommended by the largest shareholder, Dunhua Jincheng Industrial Co., Ltd., which holds 27.35% of the company's shares [78][79] - The independent director candidate must pass the qualification and independence review by the Shenzhen Stock Exchange before the shareholders' meeting can vote on the proposal [79] Group 3 - The company ensures that the notice for the extraordinary general meeting complies with relevant laws and regulations, including the Company Law and the Shenzhen Stock Exchange rules [83] - The meeting will adopt a combination of on-site and online voting methods, with specific voting times outlined [84][86] - Shareholders must register to attend the meeting, with detailed registration procedures provided [93][94]

Core Viewpoint - Jilin Aodong has announced the nomination of Ms. Zhang Chunying as an independent director candidate for the company's 11th Board of Directors [2] Company Summary - Jilin Aodong has made a formal announcement regarding the nomination of a new independent director [2]

关于独立董事离任暨补选独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 吉林敖东药业股份有限公司（以下简称"公司"）于 2025 年 11 月 6 日召开 第十一届董事会第二十次会议审议通过了《关于独立董事离任暨补选独立董事的 议案》。现将相关事项公告如下： 一、独立董事离任情况 公司董事会于 2025 年 11 月 5 日收到独立董事梁毕明先生递交的书面辞呈。 梁毕明先生因个人原因，提请辞去公司第十一届董事会独立董事、董事会审计委 员会主任委员职务及提名委员会委员职务，辞职后不在公司及控股子公司任职。 梁毕明先生的原定任职期间为 2023 年 7 月 17 日至 2026 年 7 月 16 日。截至 本公告披露日，梁毕明先生未持有公司股份，不存在未履行完毕的公开承诺。 为保障公司董事会工作的正常开展，确保公司董事人数以及独立董事人数 符合《上市公司独立董事管理办法》《公司章程》等有关规定，梁毕明先生离任 将自公司股东会选举产生新任独立董事后生效。在此期间，独立董事梁毕明先生 仍继续履行独立董事及董事会专门委员会的相应职责。 梁毕明先生在公司任职 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-062 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交 易所业务规则规定的独立董事任职资格和条件。 吉林敖东药业集团股份有限公司 独立董事提名人声明与承诺 提名人敦化市金诚实业有限责任公司现就提名张春颖女士为吉林敖东药业 集团股份有限公司第十一届董事会独立董事候选人发表公开声明。被提名人已书 面同意作为吉林敖东药业集团股份有限公司第十一届董事会独立董事候选人（参 见该独立董事候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、 详细的工作经历、全部兼职、有无重大失信等不良记录等情况后作出的，本提名 人认为被提名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交 易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下 事项： 一 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-061 吉林敖东药业集团股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会第二十次会议决 议召开公司 2025 年第二次临时股东会（以下简称"本次股东会"），本次股东会采用现场 投票和网络投票相结合的表决方式，现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法、合规性：经公司第十一届董事会第二十次会议审议通过，决定召 开公司 2025 年第二次临时股东会，本次会议的召集、召开符合《中华人民共和国公司法》 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 24 日 14:00 （2）网络投票时间：通过深圳证券交易所系 ...

证券代码：000623 证券简称：吉林敖东 公告编号:2025-059 二、董事会会议审议情况 1、审议《关于独立董事离任暨补选独立董事的议案》 吉林敖东药业集团股份有限公司 第十一届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第二十次会议通知以书面方式于 2025 年 11 月 3 日发出。 2、会议于 2025 年 11 月 6 日在公司六楼会议室以现场结合通讯方式召开。 3、本次会议公司应到董事 9 名，实际参加会议董事 9 名，其中：独立董事 李鹏先生、肖维维女士、梁毕明先生以通讯表决方式出席本次会议。 4、会议由公司董事长李秀林先生主持，公司高级管理人员列席本次董事会 会议。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 三、备查文件 1、公司第十一届董事会第二十次会议决议； 表决结果：通过。同意票 9 票，反对票 0 票，弃权票 0 票。 全文详见公司于 2025 年 11 月 7 日 ...